Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 407

1.

Curing HIV/AIDS beyond hematopoietic stem cell transplant.

Shearer GM, Clerici M, Graham DR, Boasso A.

AIDS. 2015 Nov;29(17):2364-6. doi: 10.1097/QAD.0000000000000861. No abstract available.

2.

Attenuation of pathogenic immune responses during infection with human and simian immunodeficiency virus (HIV/SIV) by the tetracycline derivative minocycline.

Drewes JL, Szeto GL, Engle EL, Liao Z, Shearer GM, Zink MC, Graham DR.

PLoS One. 2014 Apr 14;9(4):e94375. doi: 10.1371/journal.pone.0094375. eCollection 2014.

3.

Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques.

Vaccari M, Fenizia C, Ma ZM, Hryniewicz A, Boasso A, Doster MN, Miller CJ, Lindegardh N, Tarning J, Landay AL, Shearer GM, Franchini G.

AIDS Res Hum Retroviruses. 2014 Apr;30(4):355-62. doi: 10.1089/AID.2013.0218. Epub 2013 Dec 24.

4.

Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2',3'-dideoxyinosine and stavudine following cytotoxic-T-lymphocyte-associated antigen 4 and indoleamine 2,3-dioxygenase blockade.

Vaccari M, Boasso A, Fenizia C, Fuchs D, Hryniewicz A, Morgan T, Weiss D, Doster MN, Heraud JM, Shearer GM, Franchini G.

J Virol. 2012 Jan;86(1):108-13. doi: 10.1128/JVI.05609-11. Epub 2011 Oct 19.

5.

Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis.

Boasso A, Royle CM, Doumazos S, Aquino VN, Biasin M, Piacentini L, Tavano B, Fuchs D, Mazzotta F, Lo Caputo S, Shearer GM, Clerici M, Graham DR.

Blood. 2011 Nov 10;118(19):5152-62. doi: 10.1182/blood-2011-03-344218. Epub 2011 Sep 19.

6.

Alloantigen-based AIDS vaccine: revisiting a "rightfully" discarded promising strategy.

Shearer GM, Boasso A.

F1000 Med Rep. 2011;3:12. doi: 10.3410/M3-12. Epub 2011 Jun 1.

7.

Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection.

Kemp TJ, Hildesheim A, García-Piñeres A, Williams MC, Shearer GM, Rodriguez AC, Schiffman M, Burk R, Freer E, Bonilla J, Herrero R, Pinto LA.

Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1954-9. doi: 10.1158/1055-9965.EPI-10-0184. Epub 2010 Jul 20.

8.

TLR activation pathways in HIV-1-exposed seronegative individuals.

Biasin M, Piacentini L, Lo Caputo S, Naddeo V, Pierotti P, Borelli M, Trabattoni D, Mazzotta F, Shearer GM, Clerici M.

J Immunol. 2010 Mar 1;184(5):2710-7. doi: 10.4049/jimmunol.0902463. Epub 2010 Feb 1.

10.

Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo.

Poirier MC, Olivero OA, Hardy AW, Franchini G, Borojerdi JP, Walker VE, Walker DM, Shearer GM.

AIDS Res Ther. 2009 Nov 6;6:24. doi: 10.1186/1742-6405-6-24.

11.

WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.

Walker DM, Kajon AE, Torres SM, Carter MM, McCash CL, Swenberg JA, Upton PB, Hardy AW, Olivero OA, Shearer GM, Poirier MC, Walker VE.

Environ Mol Mutagen. 2009 Jul;50(6):460-72. doi: 10.1002/em.20482.

12.

Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques.

Boasso A, Vaccari M, Fuchs D, Hardy AW, Tsai WP, Tryniszewska E, Shearer GM, Franchini G.

J Immunol. 2009 Apr 1;182(7):4313-20. doi: 10.4049/jimmunol.0803314.

13.

Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?

Boasso A, Shearer GM, Chougnet C.

J Intern Med. 2009 Jan;265(1):78-96. doi: 10.1111/j.1365-2796.2008.02043.x. Review.

14.

Introduction: Back to basics: mucosal immunity and novel HIV vaccine concepts.

Broliden K, Haase AT, Ahuja SK, Shearer GM, Andersson J.

J Intern Med. 2009 Jan;265(1):5-17. doi: 10.1111/j.1365-2796.2008.02053.x. No abstract available.

15.

CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.

Vaccari M, Boasso A, Ma ZM, Cecchinato V, Venzon D, Doster MN, Tsai WP, Shearer GM, Fuchs D, Felber BK, Pavlakis GN, Miller CJ, Franchini G.

Mucosal Immunol. 2008 Nov;1(6):497-507. doi: 10.1038/mi.2008.60. Epub 2008 Sep 17.

PMID:
19079217
16.

HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques.

Herbeuval JP, Nilsson J, Boasso A, Hardy AW, Vaccari M, Cecchinato V, Valeri V, Franchini G, Andersson J, Shearer GM.

AIDS. 2009 Jan 2;23(1):35-40. doi: 10.1097/QAD.0b013e32831cb907.

PMID:
19050384
17.

HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation.

Boasso A, Hardy AW, Anderson SA, Dolan MJ, Shearer GM.

PLoS One. 2008 Aug 13;3(8):e2961. doi: 10.1371/journal.pone.0002961.

18.

PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes.

Boasso A, Hardy AW, Landay AL, Martinson JL, Anderson SA, Dolan MJ, Clerici M, Shearer GM.

Clin Immunol. 2008 Oct;129(1):132-44. doi: 10.1016/j.clim.2008.05.009. Epub 2008 Jul 22.

19.

The hunt for an HIV vaccine: time to rethink recent failures.

Boasso A, Shearer GM, Clerici M.

Lancet. 2008 Jun 7;371(9628):1897-8. doi: 10.1016/S0140-6736(08)60812-0. No abstract available.

PMID:
18539209
20.

Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells.

Cano OD, Neurauter G, Fuchs D, Shearer GM, Boasso A.

Neurosci Lett. 2008 Jun 13;438(1):22-5. doi: 10.1016/j.neulet.2008.04.046. Epub 2008 Apr 18.

PMID:
18457922
21.

Animal models of acute and chronic graft-versus-host disease.

Hakim F, Fowler DH, Shearer GM, Gress RE.

Curr Protoc Immunol. 2001 May;Chapter 4:Unit 4.3. doi: 10.1002/0471142735.im0403s27.

PMID:
18432794
22.

Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection.

Cecchinato V, Tryniszewska E, Ma ZM, Vaccari M, Boasso A, Tsai WP, Petrovas C, Fuchs D, Heraud JM, Venzon D, Shearer GM, Koup RA, Lowy I, Miller CJ, Franchini G.

J Immunol. 2008 Apr 15;180(8):5439-47.

23.

HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha.

Hardy AW, Graham DR, Shearer GM, Herbeuval JP.

Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17453-8. Epub 2007 Oct 23.

24.

Chronic innate immune activation as a cause of HIV-1 immunopathogenesis.

Boasso A, Shearer GM.

Clin Immunol. 2008 Mar;126(3):235-42. Epub 2007 Oct 3. Review.

25.

Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection.

Boasso A, Vaccari M, Hryniewicz A, Fuchs D, Nacsa J, Cecchinato V, Andersson J, Franchini G, Shearer GM, Chougnet C.

J Virol. 2007 Nov;81(21):11593-603. Epub 2007 Aug 22.

26.

Regulatory T cells (Treg) and HIV/AIDS: summary of the September 7-8, 2006 workshop.

Chougnet CA, Shearer GM.

AIDS Res Hum Retroviruses. 2007 Jul;23(7):945-52.

PMID:
17678480
27.

How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation.

Boasso A, Shearer GM.

Curr Drug Metab. 2007 Apr;8(3):217-23. Review.

PMID:
17430110
28.

Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques.

Hryniewicz A, Price DA, Moniuszko M, Boasso A, Edghill-Spano Y, West SM, Venzon D, Vaccari M, Tsai WP, Tryniszewska E, Nacsa J, Villinger F, Ansari AA, Trindade CJ, Morre M, Brooks D, Arlen P, Brown HJ, Kitchen CM, Zack JA, Douek DC, Shearer GM, Lewis MG, Koup RA, Franchini G.

J Immunol. 2007 Mar 15;178(6):3492-504.

29.

HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells.

Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D, Shearer GM.

Blood. 2007 Apr 15;109(8):3351-9. Epub 2006 Dec 7.

30.

HIV-1 immunopathogenesis: how good interferon turns bad.

Herbeuval JP, Shearer GM.

Clin Immunol. 2007 May;123(2):121-8. Epub 2006 Nov 16. Review.

31.

Do regulatory T-cells play a role in AIDS pathogenesis?

Boasso A, Vaccari M, Nilsson J, Shearer GM, Andersson J, Cecchinato V, Chougnet C, Franchini G.

AIDS Rev. 2006 Jul-Sep;8(3):141-7. Review.

PMID:
17078484
32.

Ribonucleases in HIV type 1 inhibition: effect of recombinant RNases on infection of primary T cells and immune activation-induced RNase gene and protein expression.

Bedoya VI, Boasso A, Hardy AW, Rybak S, Shearer GM, Rugeles MT.

AIDS Res Hum Retroviruses. 2006 Sep;22(9):897-907.

PMID:
16989616
33.

HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS.

Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, Shearer GM, Andersson J, Chougnet C.

Blood. 2006 Dec 1;108(12):3808-17. Epub 2006 Aug 10.

34.

CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.

Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai WP, Heraud JM, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G.

Blood. 2006 Dec 1;108(12):3834-42. Epub 2006 Aug 8. Erratum in: Blood. 2009 Oct 1;114(14):3132.

35.

Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?

Herbeuval JP, Shearer GM.

AIDS Rev. 2006 Jan-Mar;8(1):3-8. Review.

PMID:
16736946
36.

Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.

Herbeuval JP, Nilsson J, Boasso A, Hardy AW, Kruhlak MJ, Anderson SA, Dolan MJ, Dy M, Andersson J, Shearer GM.

Proc Natl Acad Sci U S A. 2006 May 2;103(18):7000-5. Epub 2006 Apr 21.

37.

Apoptotic T cell death in HIV/AIDS.

Clerici M, Shearer GM.

Cell Death Differ. 1997 Dec;4(8):834. No abstract available.

38.
39.

Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells.

Herbeuval JP, Hardy AW, Boasso A, Anderson SA, Dolan MJ, Dy M, Shearer GM.

Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13974-9. Epub 2005 Sep 20.

40.

CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis.

Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, Dolan MJ, Yagita H, Lifson JD, Shearer GM.

Blood. 2005 Nov 15;106(10):3524-31. Epub 2005 Jul 26.

41.

The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients.

Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, Shearer GM, Chougnet CA.

J Immunol. 2005 Mar 15;174(6):3143-7.

42.

TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells.

Herbeuval JP, Boasso A, Grivel JC, Hardy AW, Anderson SA, Dolan MJ, Chougnet C, Lifson JD, Shearer GM.

Blood. 2005 Mar 15;105(6):2458-64. Epub 2004 Dec 7.

43.

Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells.

Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM.

Blood. 2005 Feb 15;105(4):1574-81. Epub 2004 Oct 5.

44.

Alloantigen recognition in utero: dual advantage for the fetus?

Rugeles MT, Shearer GM.

Trends Immunol. 2004 Jul;25(7):348-52. Review. No abstract available.

PMID:
15207501
45.

The effect of IL-12 on clinical and laboratory aspects of experimental SLE in young and aging mice.

Segal R, Dayan M, Zinger H, Habut B, Shearer GM, Mozes E.

Exp Gerontol. 2003 Jun;38(6):661-8.

PMID:
12814801
46.

HIV inhibitory activity generated by antigen-stimulated cord blood leukocytes.

Pinto LA, Grene E, Baker R, Trubey CM, Torres N, Trivett M, Shearer GM.

AIDS. 2003 Jun 13;17(9):1389-92. No abstract available.

PMID:
12799561
47.

Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition.

Rugeles MT, Trubey CM, Bedoya VI, Pinto LA, Oppenheim JJ, Rybak SM, Shearer GM.

AIDS. 2003 Mar 7;17(4):481-6.

PMID:
12598767
48.

Study of the effect of indoleamine 2,3-dioxygenase on murine mixed lymphocyte reactions and skin allograft rejection.

Sakurai K, Zou JP, Torres NI, Tschetter JR, Kim HS, Shearer GM.

Transplant Proc. 2002 Dec;34(8):3271-3. No abstract available.

PMID:
12493443
49.

B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression.

Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, Ferrante P, Dong H, Maserati R, Shearer GM, Chen L, Clerici M.

Blood. 2003 Apr 1;101(7):2514-20. Epub 2002 Dec 5.

50.

Immunologic profile of highly exposed yet HIV type 1-seronegative men.

Yang OO, Boscardin WJ, Matud J, Hausner MA, Hultin LE, Hultin PM, Shih R, Ferbas J, Siegal FP, Shodell M, Shearer GM, Grene E, Carrington M, O'Brien S, Price CB, Detels R, Jamieson BD, Giorgi JV.

AIDS Res Hum Retroviruses. 2002 Sep 20;18(14):1051-65.

PMID:
12396457

Supplemental Content

Loading ...
Support Center